Q3-osavuosiraportti
31 päivää sitten‧1 t 51 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
1 164
Myynti
Määrä
4 389
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 444 | - | - | ||
| 189 | - | - | ||
| 3 | - | - | ||
| 1 | - | - | ||
| 7 | - | - |
Ylin
27,1VWAP
Alin
26,3VaihtoMäärä
0,4 13 198
VWAP
Ylin
27,1Alin
26,3VaihtoMäärä
0,4 13 198
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 23.10. | |
| 2025 Q2-osavuosiraportti | 16.7. | |
| 2024 Yhtiökokous | 8.5. | |
| 2025 Q1-osavuosiraportti | 6.5. | |
| 2024 Q4-osavuosiraportti | 6.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenA summary to remember Here are the most important factors that can drive value appreciation in Orexo going forward: The company is in a really good position now to start growing. AmorphOX® platform – technological leverage • Orexo has developed AmorphOX, a powder-based drug technology that provides stability and rapid absorption. • The platform opens new therapeutic areas, e.g., intranasal GLP-1 treatments for diabetes and weight management. Preclinical data show up to 7x higher plasma levels compared to oral Rybelsus®. • This can give Orexo a position in the rapidly growing GLP-1 market (forecast: 150 billion USD by 2032). Pipeline with several potential blockbusters • IZIPRY™ (OX124) – high-dose naloxone against fentanyl overdoses. FDA application is planned for summer 2026. • OX640 – intranasal epinephrine against anaphylaxis, with stability in extreme temperatures. Clinical data show rapid effect compared to injection. • OX390 – BARDA-funded rescue medicine against counterfeit opioids. Funding up to 480 Mkr upon milestones. • OX472 (semaglutide) – intranasal GLP-1 candidate for needle-free treatment. Support from the US market • Zubsolv® remains a core product against opioid dependence with 99 % market coverage in the commercial segment. EBIT margin in the US rose despite currency headwinds. • Federal initiatives in the US to combat the opioid crisis provide long-term demand. Strategic partnerships and financing • The BARDA agreement for OX390 strengthens Orexo's financial flexibility and commercially validates the technology. • Possible future licensing agreements for GLP-1 and rescue medicines can provide upfront payments and royalties. Technical and fundamental potential • The stock is in an upward trend channel in the medium term, with resistance at approx. 41,50 kr (now around 27–28 kr). Long-term momentum is positive, but short-term is weak. • Analysts' 12-month target price is around 31 kr, which is a limited upside from today's level, but with a significant option for value increase if the pipeline delivers.- ·11.11.There are not many alternatives for competitors to ARS other than OX 640 when it comes to joining the shift from injections to nasal. Both manufacturing costs and efficacy beat needle alternatives. The market is enormous and global for epinephrine against anaphylactic shock and many companies live off it and now Orexo's solution is a future for their market.
- ·11.11.ARS pharma Q3 from the report Sales increase 2.5x Q3 sales approx 325 million SEK 18000 healthcare providers have started prescribing, 87% of patients positive and 97% of doctors indicate continued prescribing. What a good development for epinephrine nasal spray in the USA, the company states that they are now moving forward globally. Overall, this strengthens Orexos' opportunities for OX640, now the bids are coming from pharmaceutical companies that want to join. Hold tight to your shares
·11.11.Neffys (ARS Pharma)'s strong revenue growth is a good sign for orexo to succeed in signing an agreement OX640- ·10.11.Shares post from Julia placera forum: ARS (neffy) Orexo competitor ARS reports its Q3 earnings today. Increased revenue by 2.5 compared to the previous Q report. Forecasts a strong increase going forward. This is extra encouraging considering that this is exactly what potential partners for Orexo 640 have looked at, and been afraid that the market is not big enough. ARS has increased and will increase significantly going forward as nasal is the future. This strengthens Orexo even more in partner negotiations and one can get well paid. Orexo has proven to be better than ARS neffy and has better durability. ARS is soaring on the stock market today. Good news for ARs = good for Orexo 😀😀😀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
31 päivää sitten‧1 t 51 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenA summary to remember Here are the most important factors that can drive value appreciation in Orexo going forward: The company is in a really good position now to start growing. AmorphOX® platform – technological leverage • Orexo has developed AmorphOX, a powder-based drug technology that provides stability and rapid absorption. • The platform opens new therapeutic areas, e.g., intranasal GLP-1 treatments for diabetes and weight management. Preclinical data show up to 7x higher plasma levels compared to oral Rybelsus®. • This can give Orexo a position in the rapidly growing GLP-1 market (forecast: 150 billion USD by 2032). Pipeline with several potential blockbusters • IZIPRY™ (OX124) – high-dose naloxone against fentanyl overdoses. FDA application is planned for summer 2026. • OX640 – intranasal epinephrine against anaphylaxis, with stability in extreme temperatures. Clinical data show rapid effect compared to injection. • OX390 – BARDA-funded rescue medicine against counterfeit opioids. Funding up to 480 Mkr upon milestones. • OX472 (semaglutide) – intranasal GLP-1 candidate for needle-free treatment. Support from the US market • Zubsolv® remains a core product against opioid dependence with 99 % market coverage in the commercial segment. EBIT margin in the US rose despite currency headwinds. • Federal initiatives in the US to combat the opioid crisis provide long-term demand. Strategic partnerships and financing • The BARDA agreement for OX390 strengthens Orexo's financial flexibility and commercially validates the technology. • Possible future licensing agreements for GLP-1 and rescue medicines can provide upfront payments and royalties. Technical and fundamental potential • The stock is in an upward trend channel in the medium term, with resistance at approx. 41,50 kr (now around 27–28 kr). Long-term momentum is positive, but short-term is weak. • Analysts' 12-month target price is around 31 kr, which is a limited upside from today's level, but with a significant option for value increase if the pipeline delivers.
- ·11.11.There are not many alternatives for competitors to ARS other than OX 640 when it comes to joining the shift from injections to nasal. Both manufacturing costs and efficacy beat needle alternatives. The market is enormous and global for epinephrine against anaphylactic shock and many companies live off it and now Orexo's solution is a future for their market.
- ·11.11.ARS pharma Q3 from the report Sales increase 2.5x Q3 sales approx 325 million SEK 18000 healthcare providers have started prescribing, 87% of patients positive and 97% of doctors indicate continued prescribing. What a good development for epinephrine nasal spray in the USA, the company states that they are now moving forward globally. Overall, this strengthens Orexos' opportunities for OX640, now the bids are coming from pharmaceutical companies that want to join. Hold tight to your shares
- ·11.11.Neffys (ARS Pharma)'s strong revenue growth is a good sign for orexo to succeed in signing an agreement OX640
- ·10.11.Shares post from Julia placera forum: ARS (neffy) Orexo competitor ARS reports its Q3 earnings today. Increased revenue by 2.5 compared to the previous Q report. Forecasts a strong increase going forward. This is extra encouraging considering that this is exactly what potential partners for Orexo 640 have looked at, and been afraid that the market is not big enough. ARS has increased and will increase significantly going forward as nasal is the future. This strengthens Orexo even more in partner negotiations and one can get well paid. Orexo has proven to be better than ARS neffy and has better durability. ARS is soaring on the stock market today. Good news for ARs = good for Orexo 😀😀😀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
1 164
Myynti
Määrä
4 389
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 444 | - | - | ||
| 189 | - | - | ||
| 3 | - | - | ||
| 1 | - | - | ||
| 7 | - | - |
Ylin
27,1VWAP
Alin
26,3VaihtoMäärä
0,4 13 198
VWAP
Ylin
27,1Alin
26,3VaihtoMäärä
0,4 13 198
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 23.10. | |
| 2025 Q2-osavuosiraportti | 16.7. | |
| 2024 Yhtiökokous | 8.5. | |
| 2025 Q1-osavuosiraportti | 6.5. | |
| 2024 Q4-osavuosiraportti | 6.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
31 päivää sitten‧1 t 51 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 23.10. | |
| 2025 Q2-osavuosiraportti | 16.7. | |
| 2024 Yhtiökokous | 8.5. | |
| 2025 Q1-osavuosiraportti | 6.5. | |
| 2024 Q4-osavuosiraportti | 6.2. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenA summary to remember Here are the most important factors that can drive value appreciation in Orexo going forward: The company is in a really good position now to start growing. AmorphOX® platform – technological leverage • Orexo has developed AmorphOX, a powder-based drug technology that provides stability and rapid absorption. • The platform opens new therapeutic areas, e.g., intranasal GLP-1 treatments for diabetes and weight management. Preclinical data show up to 7x higher plasma levels compared to oral Rybelsus®. • This can give Orexo a position in the rapidly growing GLP-1 market (forecast: 150 billion USD by 2032). Pipeline with several potential blockbusters • IZIPRY™ (OX124) – high-dose naloxone against fentanyl overdoses. FDA application is planned for summer 2026. • OX640 – intranasal epinephrine against anaphylaxis, with stability in extreme temperatures. Clinical data show rapid effect compared to injection. • OX390 – BARDA-funded rescue medicine against counterfeit opioids. Funding up to 480 Mkr upon milestones. • OX472 (semaglutide) – intranasal GLP-1 candidate for needle-free treatment. Support from the US market • Zubsolv® remains a core product against opioid dependence with 99 % market coverage in the commercial segment. EBIT margin in the US rose despite currency headwinds. • Federal initiatives in the US to combat the opioid crisis provide long-term demand. Strategic partnerships and financing • The BARDA agreement for OX390 strengthens Orexo's financial flexibility and commercially validates the technology. • Possible future licensing agreements for GLP-1 and rescue medicines can provide upfront payments and royalties. Technical and fundamental potential • The stock is in an upward trend channel in the medium term, with resistance at approx. 41,50 kr (now around 27–28 kr). Long-term momentum is positive, but short-term is weak. • Analysts' 12-month target price is around 31 kr, which is a limited upside from today's level, but with a significant option for value increase if the pipeline delivers.
- ·11.11.There are not many alternatives for competitors to ARS other than OX 640 when it comes to joining the shift from injections to nasal. Both manufacturing costs and efficacy beat needle alternatives. The market is enormous and global for epinephrine against anaphylactic shock and many companies live off it and now Orexo's solution is a future for their market.
- ·11.11.ARS pharma Q3 from the report Sales increase 2.5x Q3 sales approx 325 million SEK 18000 healthcare providers have started prescribing, 87% of patients positive and 97% of doctors indicate continued prescribing. What a good development for epinephrine nasal spray in the USA, the company states that they are now moving forward globally. Overall, this strengthens Orexos' opportunities for OX640, now the bids are coming from pharmaceutical companies that want to join. Hold tight to your shares
- ·11.11.Neffys (ARS Pharma)'s strong revenue growth is a good sign for orexo to succeed in signing an agreement OX640
- ·10.11.Shares post from Julia placera forum: ARS (neffy) Orexo competitor ARS reports its Q3 earnings today. Increased revenue by 2.5 compared to the previous Q report. Forecasts a strong increase going forward. This is extra encouraging considering that this is exactly what potential partners for Orexo 640 have looked at, and been afraid that the market is not big enough. ARS has increased and will increase significantly going forward as nasal is the future. This strengthens Orexo even more in partner negotiations and one can get well paid. Orexo has proven to be better than ARS neffy and has better durability. ARS is soaring on the stock market today. Good news for ARs = good for Orexo 😀😀😀
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
1 164
Myynti
Määrä
4 389
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 444 | - | - | ||
| 189 | - | - | ||
| 3 | - | - | ||
| 1 | - | - | ||
| 7 | - | - |
Ylin
27,1VWAP
Alin
26,3VaihtoMäärä
0,4 13 198
VWAP
Ylin
27,1Alin
26,3VaihtoMäärä
0,4 13 198
Välittäjätilasto
Dataa ei löytynyt